Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24145961 | 0.84 | USP2 (0.47) | USP2SMN1; SMN2EPHX2EPHX1HPGD | |
| SCHEMBL2420832 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2EPHX2EPHX1PKM | |
| SCHEMBL4287443 | 0.81 | USP2 (0.50) | USP2SMN1; SMN2EPHX2EPHX1PKM | |
| SCHEMBL27302819 | 0.81 | USP2 (0.44) | USP2SMN1; SMN2EPHX2EPHX1PKM | |
| SCHEMBL3498315 | 0.80 | USP2 (0.49) | USP2SMN1; SMN2EPHX2EPHX1PKM | |
| SCHEMBL5896147 | 0.80 | USP2 (0.49) | USP2SMN1; SMN2EPHX2EPHX1PKM | |
| SCHEMBL31669897 | 0.79 | USP2 (0.37) | USP2SMN1; SMN2EPHX2EPHX1PKM | |
| SCHEMBL31693653 | 0.79 | GPR119 (0.46) | USP2SMN1; SMN2EPHX2EPHX1PKM | |
| SCHEMBL29207322 | 0.78 | HDAC2 (0.39) | USP2SMN1; SMN2EPHX2EPHX1PKM | |
| SCHEMBL30849782 | 0.78 | HDAC2 (0.39) | USP2SMN1; SMN2EPHX2EPHX1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3876928-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20210403479-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210403479-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2021-12-30 | — | — | US | disclosed |
| EP-3876928-A2 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | Merck Sharp & Dohme Corp. (US) | 2021-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403479-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | HDAC1, HDAC11, HDAC3 | USP2 2060/4885SMN1; SMN2 4336/4885EPHX2 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.